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Abstract
Background: CD4+CD25+ regulatory T (Treg) cells suppress tumor immunity by inhibiting immune cells. Manipulation
of Treg cells represents a new strategy for cancer treatment. Zoledronic acid (ZA), a nitrogen-containing
bisphosphonate, inhibits the expression of receptor activator of nuclear factor kappa-B ligand (RANKL) on osteoblasts
to inhibit osteoclastogenesis. In a mouse model of bisphosphonate-related osteonecrosis of the jaw, administration of
ZA suppressed Treg-cell activity and activated inflammatory Th17 cells. However, the interaction between ZA and Treg
cells remained unclear. This study investigated the immune modulation of Treg cells by ZA.
Methods: Flow cytometry was used to analyze the phenotypic and immunosuppressive characteristics of Treg cells
treated with ZA. Chemotactic migration was evaluated using transwell assays. Quantitative real-time PCR (qRT-PCR) was
used to investigate the effect of ZA on the expression of suppressive molecules by Treg cells.
Results: Proliferation of isolated Treg cells in culture was inhibited by ZA, although ZA did not induce apoptosis.
qRT-PCR and flow cytometry showed that ZA significantly downregulated the expression of CCR4, CTLA4, PD-1 and
RANKL on Treg cells. Chemotactic migration and immunosuppressive functions were also significantly attenuated in
Treg cells pretreated with ZA, and these effects were dose-dependent. Co-culture with Treg cells significantly increased
the migration rate of breast cancer cells, while pretreatment of Treg cells with ZA attenuated this effect.
Conclusions: Our findings demonstrated that ZA acted as an immune modulator by significantly inhibiting the
expansion, migration, immunosuppressive function and pro-metastatic ability of Treg cells. Immunomodulation of Treg
cells by ZA represents a new strategy for cancer therapy.
Keywords: Regulatory T cells, Zoledronic acid, Immunomodulation, Breast cancer
Background
Regulatory T (Treg) cells comprise a subset of CD4+CD25
+ T lymphocytes, and function to suppress the immune
response [1, 2]. Infiltration of Treg cells into the tumor
microenvironment was shown to promote tumor cell
escape from immune surveillance, and contribute to
tumor growth and progression, suggesting that Treg cells
play an important role in the prognosis of cancer patients
[3–6]. Studies investigating the mechanisms of Treg cell-
mediated promotion of tumor growth showed that the
differentiation, expansion, recruitment, and activation of
Treg cells in tumors potently abrogated antitumor
immunity and promoted local tumor growth [7–9]. It was
previously reported that increased Treg-cell accumulation
in breast cancer was associated with poor prognosis [4].
Using a transgenic mouse model, it was recently shown
that tumor-infiltrating Treg cells are the major source of
receptor activator of NF-kB ligand (RANKL), which facili-
tates metastasis of RANK-expressing breast cancer cells
[10]. Therefore, manipulation of Treg cells to promote a
more effective immune response to tumors may represent
a feasible immunotherapeutic strategy for breast cancer.
Furthermore, the identification of new therapeutic targets
to combat tumor-induced immune suppression is
dependent on elucidating the mechanisms of 1) Treg-cell
trafficking and accumulation in the tumor microenviron-
ment and 2) the interaction between cancer cells and Treg
cells [11].
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Zoledronic acid (ZA) is a third-generation nitrogen-
containing bisphosphonate (BP) and is able to suppress
osteoclastogenesis via the inhibition of RANKL expres-
sion on osteoblasts [12, 13]. Some preclinical and clinical
findings suggested that ZA also has anti-tumor and anti-
metastatic properties, and ZA has been reported to in-
hibit angiogenesis, suppress tumor cell invasion, induce
tumor cell apoptosis and induce cytotoxic γδ T cells
[14–19]. ZA is currently used as an adjuvant treatment
for early stage breast cancers. The phase III Austrian
Breast and Colorectal Cancer Study Group trial 12
(ABCSG-12) recently reported that the addition of ZA
to endocrine therapy increased the duration of disease-
free survival in patients with estrogen receptor-positive
breast cancer. ZA was shown to reduce both local re-
gional and distant metastases, suggesting that it might
act directly on micrometastases of breast cancer cells
[20]. The Zometa-Femara Adjuvant Synergy Trial (ZO-
FAST), which was the largest study using ZA, also
showed encouraging results when ZA was added to the
adjuvant therapy of breast cancer [21]. More recently,
data from the Adjuvant Zoledronic acid to reduce recur-
rence (AZURE) trial also suggested that ZA potentiated
the activity of adjuvant endocrine therapy in postmeno-
pausal patients [22]. Furthermore, a mouse model of
ZA-related osteonecrosis of the jaw showed that ZA
inhibited Treg-cell activity [23]. Although the immuno-
modulatory effect of ZA was proposed as being related
to Treg cells, the interaction between ZA and Treg cells
was unclear. The aim of this study was to investigate
how ZA affected tumor immunity via Treg cells.
Methods
Isolation and expansion of regulatory T cells
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from 100 ml of fresh heparinized peripheral blood
from healthy volunteers by Ficoll-Hypaque (GE Health-
care, Uppsala, Sweden) gradient centrifugation. The cells
from the interface were washed three times in HBSS and
seeded in 6-well microtiter plates in RPMI-1640 medium,
and allowed to settle at 37 °C in a humidified atmosphere
with 5% CO2. After 30 min, the non-adherent cells were
collected as lymphocytes. Treg cells were immediately
purified from PBMCs by immunomagnetic separation
using the Dynabeads® Regulatory CD4+CD25+ T Cell Kit
(Invitrogen™, Oslo, Norway), according to the manufac-
turer’s instructions. In brief, CD4+ cells were isolated by
negative selection after depletion of cells expressing CD8,
CD14, CD16, CD19, CD36, CDw123, CD235a and CD56.
CD25+ cells were then selected by positive selection using
magnetic beads directly conjugated to an anti-CD25 Ab.
The procedure yielded a highly pure preparation (>95%
purity) of regulatory CD4+CD25+ T cells, more than 80%
of which expressed the intracellular transcription factor,
Foxp3. The isolated Treg cells were expanded with
Dynabeads® Human Treg Expander (Gibco®, Oslo,
Norway) containing 100 U/ml rIL2 (Gibco®, Carlsbad, CA,
USA). The study was approved by the Institutional Review
Committee of E-DA Hospital and the volunteers provided
written informed consent.
Chemicals, antibodies and cell line
Zoledronic acid (ZA) was provided by Novartis Pharma
AG Basel, Switzerland. Monoclonal antibodies against
human CD25-PE, CD152 (CTLA-4)-PE, FOXP3-FITC,
and CD279 (PD-1)-FITC were purchased from
eBioscience, San Diego, CA, USA. CD194 (CCR4)-
PerCP-CyTM 5.5, and CD69-FITC were purchased from
BD Biosciences, San Jose, CA, USA. The MDA-MB-231
breast cancer cell line was purchased from the American
Type Culture Collection (Food Industry Research and
Development Institute, Taiwan) and was cultured with
DMEM medium (Gibco®, Grand Island, NY, USA), con-
taining 10% fetal bovine serum (FBS: Biological indus-
tries, Kibbutz Beit HaEmek, Israel). Conditioned media
(CM) harvested from MDA-MB-231 cells consisted of
DMEM supplemented with 2% FBS in which cells were
cultured for 48 h. CM was collected, sterile filtered and
stored in aliquots at −80 °C.
Proliferation assay
Expanded Tregs and lymphocytes were labelled with
2 μM carboxyflourescein diacetate succinimidyl ester
(CFSE) (BD Biosciences, San Jose, CA) at 37 °C for
15 min. The cells were seeded in 12-well plates at a
density of 2.5 × 106 cells/well, cultured with culture
medium in 0, 10 and 100 μM ZA, and stimulated with
CD3/CD28 micro beads. The culture media was changed
every 3 days and measured. They were analyzed using
the Cell Quest Pro software (BD Biosciences, San Jose,
CA) or WinMDI software.
Treg cells apoptosis assays
Apoptosis of Treg cells was analyzed by seeding Treg
cells at a density of 5 × 105cells/well, and starving them
overnight in serum free DMEM. The cells were then
treated with ZA (0 or 100 μM) for 24 h in DMEM sup-
plemented with 2% FBS. Cells were harvested and incu-
bated with FITC-labeled Annexin V and Propidium
Iodide Staining Solution (eBioscience, San Diego, CA,
USA). The percentages of apoptotic and necrotic cells
were determined by flow cytometry (FACScalibur; BD
Biosciences, San Jose, CA, USA). Five parallel samples
were measured and 10,000 events were analyzed using
Cell Quest Pro software (BD Biosciences, San Jose, CA,
USA) or WinMDI software (San Diego, CA, USA). In
addition, Treg cells were centrifuged onto microscope
slides using a Cytospin2 centrifuge (Shandon Inc.,
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Pittsburgh, PA, USA); the slides were stained with
Wright-Giemsa solution and observed by light micros-
copy (Olympus, Tokyo, Japan).
Treg cells migration assays
Migration assays were performed in 24-well transwell
chambers (Corning, New York, NY, USA) using 8-μm
pore polycarbonate filters. Treg cells pre-treated for 4 h
with different concentrations of ZA (0, 50 and 100 μM)
were added to the inner chamber in serum-free RPMI
medium in a final volume of 100 μL. The chemoattrac-
tants, including 2% FBS-containing DMEM or CM from
MDA-MB-231 cells, were placed in the bottom chamber
of the transwells in a total volume of 650 μL. Transwell
chambers were incubated at 37 °C for 2 h, and the num-
ber of cells in the lower chamber was counted. The
chemotaxis index was calculated by dividing the
numbers of cells migrated in response to CM of MDA-
MB-231 cells or after pretreatment with ZA by the
numbers of cells migrated in response to medium only.
Wound healing migration assay
For wound healing migration assays, MDA-MB-231 cells
were cultured in 6-cm dishes at a density of 1 × 106
cells/dish until confluent (0 h). A straight scratch was
made in the center of the plate using a 200 μL pipette-
tip. The MDA-MB-231 cells were then incubated for
12 h with Treg cells, which had been pre-treated with
ZA (0, 25, 50 or 100 μM) for 24 h. Wound healing was
evaluated by microscopy. The average cell migration
distances were measured using an inverted phase-
contrast microscope (Zeiss, Primovert, Germany).
Immunosuppressive function assays
Treg cells were cultured in medium or CM of MDA-
MB-231 cells for 72 h and treated with different concen-
trations of ZA for 24 h. Their immunosuppressive
activity was determined with a Human Regulatory T Cell
Function Kit (BD Biosciences, San Jose, CA, USA). In
brief, the harvested Treg cells (2x105) were co-cultured
in 24-well plates with responding effector cells (PBMC
4x105) in the presence of T-cell specific stimulated CD3/
CD28 beads. FITC-labeled CD69 was present for the
entire duration of stimulation in order to analyze the
transiently expressed CD69 on the surface of the effector
cells. After 7 h of activation, the percentage of CD69-
positive effector T cells was determined by flow cytome-
try [24]. The percent suppression was calculated by the
following formulas: 100–[(% CD69-positive in presence
of Tregs/% CD69-positive in absence of Tregs) × 100].
Quantitative real-time polymerase chain reaction assay
Treg cells were treated with various concentration of ZA
for 6 h, and total RNA was extracted using the total
RNA mini kit (Viogene, Sunnyvale, CA, USA) according
to the manufacturer’s instructions. Samples of total RNA
(1–2.5 μg) were reverse-transcribed using iScriptTM
cDNA Synthesis Kit (Bio-Rad, Foster City, CA, USA) ac-
cording to the manufacturer’s instructions. Real-time
PCR was carried out (iTaqTM Universal SYBR@ Green
Supermix; Bio-Rad, Foster City, CA, USA) with primers
specific for the human gene (Table 1). Fluorescence RT-
PCR analysis was performed using ABI PRISM 7700
Sequence Detection System (Applied Biosystems,
Warrington, WA, USA). PCR amplification was per-
formed with 1 cycle of 50 °C for 2 min, 1 cycle of 95 °C
for 15 min, and 40 cycles of 95 °C for 15 s followed by
58 °C for 1 min. Analysis of relative gene expression was
performed using the 2-ΔΔCT method [25]. The CT is
the threshold cycle number that is the minimal cycle for
sample detection. The arithmetic formula for the ΔCT
method is the difference in CT between the detected
gene and the GAPDH housekeeping gene.
Statistical analysis
Results represent at least 3 independent experiments.
Results are presented as mean ± SD. The statistical
analysis was performed using Prism version 5.00 soft-
ware (GraphPad Software, USA). All comparisons were
made between two groups with the two-tailed Student’s
t-test, among more than three groups with one-way
ANOVA. P values of <0.05 were considered statistically
significant.
Results
ZA inhibits proliferation of Treg cells
Expended Treg cells and freshly isolated lymphocytes
were treated with 10 μM ZA in order to evaluate the ef-
fect of ZA on Treg-cell proliferation. CD4+ lymphocytes
Table 1 Primer sequences used for quantitative RT-PCR for
mRNA expression
Target gene Oligonucleotide sequences (5′-3′)
Forward Reverse
Foxp3 TGA CCA AGG CTT CAT
CTG TG
GAG GAA CTC TGG GAA TGT
GC
CCR4 CTT CAG TCA CCT GGC
TGT CA
CTC AGC TGA ACC TGG CTA
CC
TGF-β GGA AAC CCA CAA CGA
AAT C
GCT CTG ATG TGT TGA AGA
AC
RANKL ACC AGC ATC AAA ATC
CCA AG
CCC CAA AGT ATG TTG CAT
CC
CTLA-4 CTC AGC TGA ACC TGG
CTA CC
CCA CTT GCA GAC ACC ATT
TG
PD-1 ATC AAA GAG AGC CTG
CGG G
GGT GGG CTG TGG GCA CT
GAPDH TGA ACG GGA AGC TCA
CTG G
TCC ACC ACC CTG TTG CTG
TA
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proliferation demonstrated no difference in the presence
of 10 μM ZA (Additional file 1: Figure S1). In contrast,
Treg-cell proliferation was significantly suppressed in
the presence of 10 μM ZA (Fig. 1a). Inhibition of prolif-
eration was observed as early as 6 days after ZA treat-
ment Treatment with 10 μM ZA for 12 days inhibited
proliferation by more than 28% (Fig. 1b). In addition,
Treg cells treated with ZA for 24 h exhibited abundant
cytoplasmic vacuoles, suggesting survival stress and early
cell injury (Fig. 1c). However, annexin V and PI staining
showed no evidence of apoptosis even in cells treated
with 100 μM ZA for 24 h (Additional file 2: Figure S2).
ZA inhibits chemotactic migration of Treg cells
Transwell assays were used to evaluate the effect of ZA
on the chemotactic migration of Treg cells in response
to DMEM supplemented with 2% FBS or CM from
MDA-MB-231 cells. We found that MDA-MB-231 cell
CM had a greater (4.12 ± 0.19 folds) increase in Treg-cell
chemotaxis compared with DMEM with 2% FBS (p <
0.001). ZA pretreatment significantly inhibited migration
of Treg cells in response to CM from MDA-MB-231
cells. However, the migration of ZA-pretreated Treg
cells was not significantly affected in the presence of
DMEM containing 2% FBS (Fig. 2).
Fig. 1 ZA inhibits Treg cells proliferation and induces cell injury. a Expanded Treg cells were labeled with CFSE and cultured in Treg cell medium
with or without 10 μM ZA. b Treg cell proliferation curves were measured based on the percentage of cells with decreased fluorescence as
compared to non-proliferating cells (0.38% at day 1). Data represent the mean values ± SEM and results from three independent experiments are
shown. Statistical significance (P < 0.01) is denoted by **. c The morphology of Treg cells was analyzed by microscopy in 100× oil immersion after
ZA treatment for 24 h
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ZA alters the phenotypic expression of Treg cells
The affinity between chemokine (C-C motif ) ligand 2
(CCL2) released by tumor cells and chemokine (C-C
motif ) receptor 4 (CCR4) expressed on Treg cells has
been shown to play a major role in the recruitment of
Treg cells to tumor sites [26, 27]. Cytotoxic T-lympho-
cyte antigen 4 (CTLA4), a surface protein receptor asso-
ciated with the transmission of an inhibitory signal to T
cells, is expressed on functional Treg cells [28, 29].
Thus, these phenotypic characteristics of Treg cells were
analyzed by flow cytometry after treatment with ZA. We
found a significant decrease in the expression of CCR4
and CTLA4 on Treg cells after treatment with 100 μM
ZA (Fig. 3). In addition, 100 μM ZA treatment signifi-
cantly decreased the mRNA expression of CCR4, but
not Foxp3 (Fig. 4a, b) as determined by qRT-PCR.
Transforming growth factor beta (TGF-β) and pro-
grammed cell death 1 (PD-1) are negative regulators of
T cell immune responses required for maintaining
peripheral tolerance by Treg cells [30–32]. We showed
that Treg cells treated with ZA exhibited a significant
decrease in the expression of PD-1 but not TGF-β
(Fig. 4c, d). Therefore, ZA effectively altered the
phenotype and function of Treg cells, in vitro.
ZA inhibits the ability of Treg cells to sustain breast
cancer cell migration
We investigated whether the ability of Treg cells to
enhance the migration of breast cancer cells was modu-
lated by ZA treatment. Wound healing assays performed
with MDA-MB 231 cells showed that co-culture with
Treg cells significantly increased the migration rate of
breast cancer cells, compared with MDA-MB 231 cells
alone (132.8 ± 9.5%, P < 0.05; Fig. 5a, b). However, when
MDA-MB-231 cells were co-cultured with Treg cells
pretreated with ZA, there was a significant and dose-
dependent decrease in their migration compared to
tumor cells co-cultured with untreated Treg cells (Fig. 5a,
b). In particular, Treg cells pretreated with 100 μM ZA
showed pronounced inhibition of MDA-MB-231 cell
migration (Fig. 5b; p < 0.05).
The metastatic spread of carcinoma cells is related to
the production of RANKL by Treg cells. ZA treatment
was previously shown to downregulate the expression of
RANKL by osteoblasts [12, 13]. Using qRT-PCR, we
showed that ZA treatment downregulated the expression
of RANKL by Treg cells in a dose-dependent manner
(Fig. 5c). These results implied that ZA-mediated down-
regulation of RANKL by Treg cells might attenuate the
ability of Treg cells to promote the migration of
MDA-MB-231 cells.
ZA inhibits immunosuppressive function of Treg cells
CD69 is an early activation marker on effector T cells,
thus we investigated whether isolated Treg cells could
suppress T cell activation after 7 h in culture. PBMCs
were cultured either alone or together with autologous
isolated Treg cells at a 2:1 ratio in the presence of anti-
CD3/CD28–coated microbeads and CD69 expression
was measured by flow cytometry. The results show that
pretreatment of Treg cells with 100 μM ZA inhibited
their immunosuppressive function, as evidenced by in-
crease expression of CD69 (16.9 ± 3.8% vs. 12.0 ± 0.5%)
(Fig. 6a), the percentage of Treg suppression was signifi-
cantly decreased (51.8 ± 4.0% vs. 44.9 ± 5.6%) (Fig. 6c).
Interestingly, pretreatment of Treg cells with CM from
MDA-MB-231 cells significantly inhibited CD69 expres-
sion on effector T cells (16.3 ± 0.4% vs. 12.1 ± 1.3%; p <
0.05), but the suppressed effect was reversed and
increased by ZA treatment in a dose-dependent manner
(Fig. 6b). The percent suppression of CM pretreated
Treg cells were significantly attenuated by 100 μM ZA
treatment (Fig. 6d).
Discussion
Patients with early-stage breast cancer and multiple
myeloma have been shown to benefit from the addition
of ZA to adjuvant endocrine therapy, or to standard
chemotherapy, respectively [20, 33]. Previous reports
have also demonstrated the efficacy of ZA therapy in
postmenopausal women, although the underlying mech-
anism is not fully understood [34, 35]. ZA treatment for
osteoporosis is frequently associated with the onset of
an acute phase reaction to the activation of γδ T cells
[36]. In contrast, human γδ T cells have been shown to
display potent cytotoxicity against various tumor cells
Fig. 2 ZA inhibits Treg cells chemotactic migration. Treg cells
(5 × 10 4) were pretreated with 0, 50 or 100 μM ZA for 4 h, and
placed in the upper chambers. Migration of Treg cells into the lower
chambers containing DMEM with 2% FBS or CM from MDA-MB-231
cells after 2 h was analyzed. The chemotaxis index shown compares
migration with the response of control cells to DMEM with 2% FBS.
Values are means ± SEM of results from three independent experiments
in duplicate. *P< 0.05, ** p< 0.01, ***p< 0.001
Liu et al. BMC Immunology  (2016) 17:45 Page 5 of 10
after pretreatment with ZA [19]. There is increasing
evidence to suggest that Treg cell-mediated immunosup-
pression plays an important role in the progression and
metastasis of breast cancer, and immune escape by
tumor cells is the major challenge to current immuno-
therapeutic strategies [37]. These studies suggested that
there is an urgent need to increase the efficacy of
immunotherapy by exploring therapeutic interventions
that inhibit the function of Treg cells in tumor-bearing
hosts [11]. The effect of ZA on the immune modulatory
function of Treg cells was previously not well under-
stood. Previous studies using ZA treatment on other
cells (oral keratinocytes and osteosarcoma cells) demon-
strated cell cycle arrest in S phase through various
Fig. 3 ZA influences the expression of markers associated with Treg cells suppressive function. Representative flow cytometry results of (a) CCR4
and (b) CTLA4 on Treg cells treated with 100 μM ZA (dotted line) and untreated Treg cells (shaded histogram). The negative control (unstained
Treg cells) is shown as an open histogram. Median fluorescence intensity (MFI) is plotted against the ZA concentration (μM); the results from four
independent experiments are shown. Significant difference in MFI determined using the one-way ANOZA;*p < 0.05
Fig. 4 Influence of ZA on mRNA expression by Treg cells. mRNA levels were evaluated by qRT-PCR in Treg cells treated with 0, 50, 100 μM ZA for
6 h. The gene expression values were normalized to GAPDH expression. The relative mRNA expression of (a) CCR4, (b) Foxp3, (c) TGFβ and (d)
PD-1 was calculated from Treg cells treated with ZA compared with untreated Treg cells. Values shown are means ± SEM of results from four
independent experiments performed in duplicate. *p < 0.05
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mechanisms. [38, 39] In this study, we showed that ZA
inhibited the proliferation and chemotactic migration of
Treg cells, thereby improving the antitumor immune re-
sponse. Recently, Ghigo et al. found a similar effect of
ZA, which down-regulated indoleamine 1,2 dioxygenase
and enabled the proliferation of T cells and inhibited the
expansion of Treg cells [40].
We evaluated the effects of ZA on Treg cells suppres-
sive function and gene expression, in vitro. Treg cells are
recruited to the stroma of developing breast tumors and
play a fundamental role in the pathogenesis of metastasis
[10]. In this study, we demonstrated for the first time
that the migration of Treg cells towards cancer cells was
significantly inhibited by ZA. ZA also inhibited the
expansion and immunosuppressive function of Treg cells
in vitro. Our data suggested that the ZA-mediated
attenuation of immune evasion and tumor progression
was effected via inhibition of Treg cell recruitment by
primary tumors, and a decrease in the number of
tumor-infiltrating Treg cells. Studies on bisphosphonate-
related osteonecrosis of the jaw (BRONJ) has shown that
administration of ZA and dexamethasone caused
BRONJ-like symptoms in mice, and this was attributed,
in part, to suppression of Treg cells and activation of the
inflammatory T-helper-producing interleukin 17 cells
(Th17). They demonstrated systemic infusion with mes-
enchymal stem cells or thymus-derived Tregs could
prevent and cure BRONJ-like disease via inhibition of
Th17 and increase in Tregs. In addition, Tregs have been
shown in vitro and in vivo to suppress Th17 cells; the
BRONJ-like mice model showed that treatment with
Zol/Dex suppressed both Tregs and the Treg/Th17 ratio
in peripheral blood [23]. ZA not only inhibited Treg-cell
function, but also enhanced cellular immunity via expan-
sion of cytotoxic γδ T cells and MHC-restricted αβ CD8
+ T cells [41]. These data, along with ours, suggested
that ZA induced immune modulation to suppress Treg--
cell functions. To the best of our knowledge, we are the
first to demonstrate that treatment with ZA blocked the
RANK/RANKL pathway to significantly inhibit cancer
cell migration induced by Treg cells. Our data were
consistent with previous studies, which suggested that
strategies to deplete Treg cells in breast cancer patients
[42, 43] may also be beneficial by reducing local
immunosuppression and removing a primary source of
RANKL required for tumor metastasis.
The concentrations of ZA used in our experiments
(25–100 μM) were much higher than the plasma levels
that are observed following intravenous administration
of the drug (about 1–2 μM) [44]. Since ZA mainly accu-
mulates in bone tissue and is retained for long periods
of time, it is possible that ZA can reach high concentra-
tions within the bone marrow microenvironment where
large numbers of functional Treg cells accumulate [45].
Fig. 5 Effects of ZA on the ability of Treg cells to enhance MDA-MB-231 cell migration. a Representative pictures of migration (wound closing) of
MDA-MB-231 cells grown as a mono-culture or co-culture with Treg cells at 0 and 12 h after wounding (100× magnification). b Quantification of
the migration distance as a percentage of the control (MDA-MB-231 cells only). c The relative RANKL mRNA expression was evaluated by qRT-PCR
from Treg cells treated with 0, 50, or 100 μM ZA for 6 h. The results from three independent experiments are shown. *P < 0.05, **p < 0.01
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In fact, bone marrow is a reservoir for Treg cells that
traffic through CXCL12/CXCR4 signals [46]. We dem-
onstrated that there may be two different mechanisms
underlying the anti-tumor effect of ZA in breast cancer.
Inhibition of Treg-cell migration by ZA could signifi-
cantly impair the recruitment of Treg cells by breast
cancer cells, resulting in reduced progression of micro-
metastatic foci in soft tissues. Alternatively, ZA could
act on breast cancer micrometastases within the bone
marrow. Although it is possible that ZA in this latter
model might directly inhibit breast cancer cell growth, it
is more likely that ZA-mediated inhibition of factors
produced by Treg cells, which promote cancer cell mi-
gration, significantly hampers the ability of tumor cells
to form distant metastases [10].
The level of Foxp3 protein expression in Treg cells is
critical for immune suppression, and knockdown of
Foxp3 was previously shown to result in impaired im-
mune suppression [47]. CTLA4 and PD-1 expression by
Treg cells is constitutive and critical to their suppressive
function [29, 32]. Additionally, the RANK-RANKL sig-
naling pathway is critically involved in regulating the
function of Treg cells in a mouse model of colitis [48].
These studies were all consistent with our data showing
that downregulation of CTLA4 and RANKL resulted in
inhibition of Treg cells’ immunosuppressive function.
Conclusions
Patients with early-stage breast cancer and multiple
myeloma have been shown to benefit from the addition
of ZA to adjuvant endocrine therapy, or to standard
chemotherapy. In this study, we demonstrated that ZA
influenced the suppressive activity of Treg cells and sig-
nificantly affected the ability of Treg cells to secrete
RANKL, which is known to promote breast cancer cell
migration. ZA acted as an immune modulator by signifi-
cantly inhibiting the expansion, migration, immunosup-
pressive function and pro-metastatic ability of Treg cells.
Our data suggested that immunomodulation of Treg
cells by ZA is a novel strategy for cancer therapy.
Additional files
Additional file 1: Figure S1. The effect of ZA on CD4+ lymphocyte
proliferation. (A) Isolated lymphocytes were labeled with CFSE, cultured in
medium with or without 10 μM ZA and sensitized with anti-CD3 and
anti-CD28 antibodies. (B) CD4+ lymphocyte proliferation curves were
measured based on the percentage of cells with decreased fluorescence
Fig. 6 ZA inhibits the immunosuppressive function of Treg cells. a Treg cells were treated with 0, 50, or 100 μM ZA for 24 h, and co-cultured with
autologous anti-CD3/CD28-stimulated PBMCs for 7 h. The percentage of CD69 expression on effector T cells was analyzed by flow cytometry. b
Treg cells were pretreated with CM from MDA-MB-231 cells for 72 h, followed by 0, 50, 100 μM ZA treatment for 24 h. The Tregs were then
co-cultured with autologous anti-CD3/CD28-stimulated PBMCs for 7 h. The percentage of CD69 expression on effector T cells was analyzed by
flow cytometry. c and d The percent suppression of the Tregs on effector T-cell without (c) and with (d) pretreated by CM from MDA-MB-231
cells after ZA treatment. The percent suppression was calculated by the following formula: 100–[(% CD69-positive in presence of Tregs/%
CD69-positive in absence of Tregs) × 100]. Values shown are means ± SEM of results from four independent experiments performed in
duplicate. *P < 0.05
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as compared to non-proliferating cells (0.4% at day 1). Data represent the
mean values ± SEM and results from three independent experiments are
shown. (TIF 134 kb)
Additional file 2: Figure S2. The effect of ZA on Treg cells apoptosis.
(A) Treg cells were treated with and without ZA (10, 50 and 100 μM) for
24 h. Apoptosis was measured by Annexin V‑FITC/PI staining and flow
cytometry. (B) Quantitative analysis of Treg cells by flow cytometry
revealed no effect of ZA on Treg cell apoptosis. (TIF 131 kb)
Abbreviations
BP: Bisphosphonate; CM: Conditioned media harvested from MDA-MB-231
cells consisted of DMEM supplemented with 2% FBS in which cells were
cultured for 48 h; CTLA4: Cytotoxic T-lymphocyte antigen 4;
PBMCs: Peripheral blood mononuclear cells; PD-1: Programmed cell death 1;
RANK: A receptor activator of NF-kB; TGF-β: Transforming growth factor beta;
Tregs: Regulatory T cells; ZA: Zoledronic acid
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